Medicine Information

Adribin

Name: Adribin
Brand: Adribin
Rating: 4.5 (117 reviews)

Injection2 mgAntineoplastic agents (Anthracyclines)ATC: L01DB01

Generic Name

Doxorubicin Hydrochloride

Manufacturer

Pharmacia & Upjohn

Country

USA

Loading images...

Price Details

Current market pricing information

Variant	Unit Price	Strip Price
adribin 2 mg injection	৳ 350.00	N/A

Description

Overview of the medicine

Adribin 2 mg Injection contains Doxorubicin, an anthracycline cytotoxic antibiotic used in the treatment of various cancers, including breast cancer, lymphoma, leukemia, and certain solid tumors. It works by interfering with DNA and RNA synthesis, leading to cell death.

Uses & Indications

Breast cancer

Lymphomas (Hodgkin's and non-Hodgkin's)

Leukemias (Acute lymphoblastic and myeloblastic)

Multiple myeloma

Soft tissue sarcomas

Osteosarcoma

Bladder cancer

Thyroid cancer

Gastric cancer

Ovarian cancer

Small cell lung cancer

Dosage

Adults

Highly individualized based on cancer type, treatment protocol, and patient factors. Typical single agent dose ranges from 60-75 mg/m² IV every 21 days or 20 mg/m² IV weekly. Cumulative lifetime dose should not exceed 450-550 mg/m² due to cardiotoxicity.

Elderly

Dose reduction may be considered, especially with impaired organ function. Careful monitoring required.

Renal_impairment

No specific dose adjustment for mild to moderate renal impairment, as excretion is primarily biliary. However, use with caution; severe impairment may require monitoring.

How to Take

Administered as a slow intravenous infusion over 3-5 minutes for bolus injection or 30-60 minutes for infusion. Intravesical instillation for bladder cancer. Avoid extravasation.

Mechanism of Action

Doxorubicin acts by several mechanisms: DNA intercalation, inhibition of topoisomerase II, and generation of free radicals. These actions lead to DNA damage, inhibition of DNA and RNA synthesis, and ultimately cell apoptosis.

Pharmacokinetics

Onset

Rapid distribution.

Excretion

Primarily biliary (40-50%), minor renal (5-12%).

Half life

Biphasic elimination, terminal half-life 20-48 hours.

Absorption

Administered intravenously, so 100% bioavailability.

Metabolism

Hepatic, to active metabolite doxorubicinol and inactive metabolites.

Side Effects

Contraindications

Severe myocardial insufficiency
Recent myocardial infarction
Severe persistent myelosuppression
Previous treatment with maximum cumulative doses of doxorubicin or other anthracyclines
Pregnancy and lactation (absolute contraindication)
Hypersensitivity to doxorubicin or other anthracyclines

Drug Interactions

Live vaccines

Avoid due to immunosuppression.

Paclitaxel, trastuzumab

Increased risk of cardiotoxicity.

Phenobarbital, phenytoin

May decrease doxorubicin levels.

Other myelosuppressive agents

Increased risk of myelosuppression.

Cyclosporine, verapamil, diltiazem

May increase doxorubicin levels due to P-glycoprotein inhibition, increasing toxicity.

Storage

Store unopened vials at 2°C to 8°C (36°F to 46°F), protected from light. Do not freeze. Reconstituted solution should be used promptly or stored refrigerated for a limited time.

Overdose

Overdose results in severe myelosuppression and potentially increased cardiotoxicity. Treatment is supportive, including blood transfusions, antibiotics for infection, and cardiac support as needed. There is no specific antidote.

Pregnancy & Lactation

Pregnancy Category D. Doxorubicin can cause fetal harm. Contraindicated during pregnancy. Women of childbearing potential should use effective contraception. Doxorubicin is excreted in breast milk; breastfeeding is contraindicated.

Frequently Asked Questions

Common questions about this medicine

Pack Sizes

1 vial per pack

Shelf Life

24-36 months for unopened lyophilized powder vials, stored at recommended conditions. Reconstituted solution has limited stability.

Availability

Available in hospitals and specialized oncology pharmacies

Approval Status

Approved by DGDA and international regulatory bodies

Patent Status

Generic (Off-patent for active ingredient)

WHO Essential Medicine

Yes

Clinical Trials

Doxorubicin has been extensively studied in numerous clinical trials since its discovery, demonstrating efficacy in a wide range of solid tumors and hematologic malignancies. Ongoing research explores new formulations (e.g., liposomal) and combination therapies to improve efficacy and reduce toxicity.

Lab Monitoring

Complete Blood Count (CBC) with differential (before each cycle and regularly)
Cardiac function (Echocardiogram or MUGA scan before treatment and periodically)
Liver function tests (LFTs)
Renal function tests (Creatinine, BUN)

Doctor Notes

Monitor cardiac function meticulously (ECG, ECHO, MUGA scan) before and during treatment.
Carefully manage myelosuppression with dose adjustments or growth factors.
Educate patients on potential side effects, especially cardiotoxicity and extravasation symptoms.
Strictly adhere to cumulative lifetime dose limits.

Patient Guidelines

Report any signs of infection (fever, sore throat) immediately.
Report any chest pain, shortness of breath, or swelling.
Stay hydrated and maintain good oral hygiene.
Avoid contact with people who have infections.
Understand the risk of hair loss and plan accordingly.

Missed Dose Advice

Contact your healthcare provider or oncologist immediately if you miss a dose. Do not double the dose to compensate for a missed one.

Driving Precautions

Doxorubicin may cause fatigue, dizziness, and other side effects that can impair your ability to drive or operate machinery. Avoid these activities if you feel unwell.

Lifestyle Advice

Maintain a healthy, balanced diet.
Avoid strenuous activities, especially if experiencing fatigue or myelosuppression.
Practice gentle exercises if tolerated, consult your doctor.
Avoid alcohol and smoking.